Coffee 'cuts advanced prostate cancer risk'December 8th, 2009 WASHINGTON - Researchers have associated coffee consumption with reduced risk of advanced prostate cancer. The finding has been presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.
GlaxoSmithKline pulls batch of swine flu vaccines in Canada over severe allergy fearsNovember 24th, 2009 more images
more imagesGlaxoSmithKline pulls swine flu vaccines in CanadaLONDON — The pharmaceutical company GlaxoSmithKline says it has advised medical staff in Canada to not use one batch of swine flu vaccine for fear it may trigger life-threatening allergies. GlaxoSmithKline spokeswoman Gwenan White said Tuesday the company issued the advice after reports that one batch of the swine flu vaccine might have caused more allergic reactions than normal.
Antigenics withdraws Oncophage application in Europe following negative recommendationNovember 20th, 2009 more images
more imagesAntigenics pulls European Oncophage applicationLEXINGTON, Mass. — Biotechnology company Antigenics Inc.
Dendreon's potential prostate cancer treatment Provenge gets May 1 FDA review dateNovember 20th, 2009 more images
more imagesDendreon's Provenge gets FDA review dateSEATTLE — Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1.
Correction: XenoPort-Glaxo drugNovember 11th, 2009 Correction: XenoPort-Glaxo drugNEW YORK — In a Nov. 9 story and headline about a Food and Drug Administration review of a drug being developed by XenoPort Inc.
XenoPort and Glaxo says FDA review of neuropathic pain drug extended 3 months, to Feb. 2010November 9th, 2009 FDA extends review of XenoPort-Glaxo pain drugNEW YORK — The Food and Drug Administration needs three more months to review an application to a neuropathic pain drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, the companies said.
Blood vessels could predict how prostate cancer would behaveNovember 4th, 2009 WASHINGTON - Blood vessels in prostate cancer could act as predictor of how it would behave, say researchers at The Ohio State University and the Harvard School of Public Health. The study of 572 men with localized prostate cancer indicates that aggressive or lethal prostate cancers tend to have blood vessels that are small, irregular and primitive in cross-section.
Merck: FDA won't accept its application for combo cholesterol pill including Pfizer's LipitorNovember 2nd, 2009 FDA won't accept Merck's application for new drugWHITEHOUSE STATION, N.J. — U.S. regulators won't accept drugmaker Merck's application for a new combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug.
Gen. Petraeus undergoes radiation treatment for prostate cancerOctober 6th, 2009 Gen. Petraeus treated for prostate cancerWASHINGTON — Gen. David Petraeus, the top U.S.
QLT says it sold US business, which treats prostate cancer symptoms, to Tolmar HoldingsOctober 1st, 2009 QLT sells US business to Tolmar for up to $230MNEW YORK — Biotechnology company QLT Inc. said Thursday it sold its U.S.
Regular exercise cuts prostate cancer riskSeptember 29th, 2009 NEW DELHI - A new study has revealed that regular exercise can help keep prostate cancer at bay. According to researchers at Duke University Medical Centre, those who were moderately active - anything equivalent to walking at a moderate pace for several hours a week - were significantly less likely to be diagnosed with prostate cancer.
Decks cleared for Orchid to market anti-infectives in USSeptember 25th, 2009 CHENNAI - Decks have been cleared for the city-based Orchid Chemicals and Pharmaceuticals for marketing the generic versions of Zosyn antibiotic, with a US district court rejecting rival Wyeth Laboratories' motion for a restraint on the sale of the drug. Wyeth had filed a suit in the District Court of Columbia against the US Food and Drug Administration's (FDA) decision to grant Orchid permission to sell generic Zosyn, chemically Piperacillin-Tazobactam, claiming the drug could harm critically ill patients.
Genetic variations behind increased prostate cancer risk identifiedSeptember 21st, 2009 LONDON - Taking a major step in prostate cancer research, scientists have found a host of genetic variations that could tell which men are at the highest risk of contracting prostate cancer. The results come from two studies today, which open up the prospect of new tests and treatments for the commonest male malignant disease.
Boffins find link between common sexual infection, prostate cancer riskSeptember 10th, 2009 WASHINGTON - A strong association between the common sexually transmitted infection, Trichomonas vaginalis, and risk of advanced and lethal prostate cancer in men has been found by researchers from Harvard School of Public Health (HSPH) and Brigham and Women's Hospital. The study appears online on September 9, 2009, on the Journal of the National Cancer Institute website and will appear in a later print edition.
Veteran House Republican Sensenbrenner has prostate cancerAugust 31st, 2009 Rep. Sensenbrenner says he has prostate cancerWASHINGTON — Rep. Jim Sensenbrenner announced Monday that he is in the early stage of prostate cancer.
